DYRK1A kinase inhibitors with emphasis on cancer

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 13, 2012, Pages 1315-1329

  Ionescu, A ^a   Dufrasne, F ^a   Gelbcke, M ^a   Jabin, I ^a   Kiss, R ^a   Lamoral Theys, D ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Anti DYRK1A compounds; Cancer; DYRK1A kinase; Neurological diseases

Indexed keywords

2 (2, 4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL) MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL) MALEIMIDE; 4, 5, 6, 7 TETRABROMO 2 DIMETHYLAMINO 1H BENZIMIDAZOLE; APIGENIN; BENZOTHIAZOLE DERIVATIVE; DUAL SPECIFICITY TYROSINE KINASE INHIBITOR 1A; EMODIN; EPIGALLOCATECHIN GALLATE; HARMINE; PROTEIN TYROSINE KINASE INHIBITOR; PURVALANOL A; QUINALIZARIN; QUINAZOLINONE DERIVATIVE; QUINOLONE; ROSCOVITINE; STAUROSPORINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; CELL CYCLE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL BINDING; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; NEOPLASM; PHARMACODYNAMICS; PROTEIN LOCALIZATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84870166164     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575112091315     Document Type: Review

References (97)

1. Becker, W.; Weber, Y.; Wetzel, K.; Eirmbter, K.; Tejedor, F.J.; Joost, H.G. Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J. Biol. Chem., 1998, 273(40), 25893-25902.
2. Aranda, S.; Laguna, A.; de la Luna, S. DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles. FASEB J., 2011, 25(2), 449-462.
3. Becker, W.; Joost, HG. Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Prog. Nucleic. Acid. Res. Mol. Biol., 1999, 62, 1-17.
4. Park, J.; Song, W.J.; Chung, K.C. Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell. Mol. Life Sci., 2009, 66(20), 3235-3240.
5. Guimera, J.; Casas, C.; Estivill, X.; Pritchard, M. Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. Genomics, 1999, 57(3), 407-418.
6. Okui, M.; Ide, T.; Morita, K.; Funakoshi, E.; Ito, F.; Ogita, K.; Yoneda, Y.; Kudoh, J.; Shimizu, N. High-level expression of the Mnb/Dyrk1A gene in brain and heart during rat early development. Genomics, 1999, 62(2), 165-171.
7. Lochhead, P.A.; Sibbet, G.; Morrice, N.; Cleghon, V. Activationloop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs. Cell, 2005, 121(6), 925-936.
8. For a recent review about DYRK1A regulation see: Becker, W.; Sippl, W. Activation, regulation, and inhibition of DYRK1A. FEBS J., 2011, 278(2), 246-256.
9. Skurat, A.V.; Dietrich, A.D. Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family protein kinases. J. Biol. Chem., 2004, 279(4), 2490-2498.
10. Laguna, A.; Aranda, S.; Barallobre, M.J.; Barhoum, R.; Fernández, E.; Fotaki, V.; Delabar, J.M.; de la Luna, S.; de la Villa, P.; Arbonés, M.L. The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. Dev. Cell., 2008, 15(6), 841-853.
11. Fernandez-Martinez, J.; Vela, E.M.; Tora-Ponsioen, M.; Ocaña, OH.; Nieto, M.A.; Galceran, J. Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A. J. Cell Sci., 2009, 122(Pt 10), 1574-1583.
12. Kim, D.; Won, J.; Shin, D.W.; Kang, J.; Kim, Y.J.; Choi, S.Y.; Hwang, M.K.; Jeong, B.W.; Kim, G.S.; Joe, C.O.; Chung, S.H.; Song, W.J. Regulation of Dyrk1A kinase activity by 14-3-3. Biochem. Biophys. Res. Commun., 2004, 323(2), 499-504.
13. Alvarez, M.; Altafaj, X.; Aranda, S.; de la Luna, S. DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding. Mol. Biol. Cell., 2007, 18(4), 1167-1178.
14. Ahn, K.J.; Jeong, H.K.; Choi, H.S.; Ryoo, S.R.; Kim, Y.J.; Goo, J.S.; Choi, S.Y.; Han, J.S.; Ha, I.; Song, W.J. DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol. Dis., 2006, 22(3), 463-472.
15. Altafaj, X.; Dierssen, M.; Baamonde, C.; Martí, E.; Visa, J.; Guimerà, J.; Oset, M.; González, J.R.; Flórez, J.; Fillat, C.; Estivill, X. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet., 2001, 10(18), 1915-1923.
16. Smith, D.J.; Stevens, M.E.; Sudanagunta, S.P.; Bronson, R.T.; Makhinson, M.; Watabe, A.M.; O'Dell, T.J.; Fung, J.; Weier, H.U.; Cheng, J.F.; Rubin, E.M. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat. Genet., 1997, 16(1), 28-36.
17. Burger, P.C.; Vogel, F.S. The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am. J. Pathol., 1973, 73(2), 457-476.
18. Olson, M.I.; Shaw, C.M.; Presenile dementia and Alzheimer's disease in mongolism. Brain., 1969, 92(1), 147-156.
19. Wisniewski, K.E.; Wisniewski, H.M.; Wen, G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol., 1985, 17(3), 278-282.
20. Kim, N.D.; Yoon, J.; Kim, J.H.; Lee, J.T.; Chon, Y.S.; Hwang, M.K.; Ha, I., Song, W.J. Putative therapeutic agents for the learning and memory deficits of people with Down syndrome. Bioorg. Med. Chem. Lett., 2006, 16(14), 3772-3776.
21. Sitz, J.H.; Baumgärtel, K.; Hämmerle, B.; Papadopoulos, C.; Hekerman, P.; Tejedor, F.J.; Becker, W.; Lutz, B. The Down syndrome candidate dual-specificity tyrosine phosphorylationregulated kinase 1A phosphorylates the neurodegeneration-related septin 4. Neuroscience, 2008, 157(3), 596-605.
22. Park, J.; Oh, Y.; Chung, K.C. Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1. BMB Rep., 2009, 42(1), 6-15.
23. Hasle, H.; Clemmensen, I.H.; Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet., 2000, 355(9199), 165-169.
24. Satgé, D.; Sasco, A.J.; Carlsen, N.L.; Stiller, C.A.; Rubie, H.; Hero, B.; de Bernardi, B.; de Kraker, J.; Coze, C.; Kogner, P.; Langmark, F.; Hakvoort-Cammel, F.G.; Beck, D.; von der Weid, N.; Parkes, S.; Hartmann, O.; Lippens, R.J.; Kamps, W.A.; Sommelet, D. A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res., 1998, 58(3), 448-452.
25. Patja, K.; Pukkala, E.; Sund, R.; Iivanainen, M.; Kaski, M. Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int. J. Cancer, 2006, 118(7), 1769-1772.
26. Yang, Q.; Rasmussen, S.A.; Friedman, J.M. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet., 2002, 359(9311), 1019-1025.
27. Baek, K.H.; Zaslavsky, A.; Lynch, R.C.; Britt, C.; Okada, Y.; Siarey, R.J.; Lensch, M.W.; Park, I.H.; Yoon, S.S.; Minami, T.; Korenberg, J.R.; Folkman, J.; Daley, G.Q.; Aird, W.C.; Galdzicki, Z.; Ryeom, S. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature, 2009, 459(7250), 1126-1130.
28. Arron, J.R.; Winslow, M.M.; Polleri, A.; Chang, C.P.; Wu, H.; Gao, X.; Neilson, J.R.; Chen, L.; Heit, J.J.; Kim, S.K.; Yamasaki, N.; Miyakawa, T.; Francke, U.; Graef, I.A.; Crabtree, G.R. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature, 2006, 441(7093), 595-600.
29. Gwack, Y.; Sharma, S.; Nardone, J.; Tanasa, B.; Iuga, A.; Srikanth, S.; Okamura, H.; Bolton, D.; Feske, S.; Hogan, P.G.; Rao, A. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature, 2006, 441(7093), 646-650.
30. Fulcher, T.; Griffin, M.; Crowley, S. Firth R, Acheson R, O'Meara N. Diabetic retinopathy in Down's syndrome. Br. J. Ophthalmol., 1998, 82(4), 407-409.
31. Patterson, D. Molecular genetic analysis of Down syndrome. Hum. Genet., 2009, 126(1), 195-214.
32. Cockerill, G.W.; Bert, A.G.; Ryan, G.R.; Gamble, J.R.; Vadas, M.A.; Cockerill, P.N. Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT. Blood, 1995, 86(7), 2689-2698.
33. Jauliac, S.; López-Rodriguez, C.; Shaw, L.M.; Brown, L.F.; Rao, A.; Toker, A. The role of NFAT transcription factors in integrinmediated carcinoma invasion. Nat. Cell. Biol., 2002, 4(7), 540-544.
34. Fougère, M.; Gaudineau, B.; Barbier, J.; Guaddachi, F.; Feugeas, J.P.; Auboeuf, D.; Jauliac, S. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene. Oncogene, 2010, 29(15), 2292-2301.
35. Mahindroo, N.; Punchihewa, C.; Fujii, N. Hedgehog-Gli signaling pathway inhibitors as anticancer agents. J. Med. Chem., 2009, 52(13), 3829-3845.
36. Peukert, S.; Miller-Moslin, K. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. Chem. Med. Chem., 2010, 5(4), 500-512.
37. Masuda, M.; Wakasaki, T.; Suzui, M.; Toh, S.; Joe, A.K.; Weinstein, I.B. Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers? Curr. Cancer Drug Targets, 2010, 10(1), 117-126.
38. Liu, Y.; Li, C.; Lin, J. STAT3 as a Therapeutic Target for Glioblastoma. Anticancer Agents Med. Chem., 2010, 10(7), 512-519.
39. Guschin, D.; Rogers, N.; Briscoe, J.; Witthuhn, B.; Watling, D.; Horn, F.; Pellegrini, S.; Yasukawa, K.; Heinrich, P.; Stark, G.R.; Ihle, J.N.; Ke, I.M. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J., 1995, 14(7), 1421-1429.
40. Jiang, L.; Wu, J.; Chen, Q.; Hu, X.; Li, W.; Hu, G. Notch1 expression is upregulated in glioma and is associated with tumor progression. J. Clin. Neurosci., 2011, 18(3), 387-390.
41. Purow, B.W.; Haque, R.M.; Noel, M.W.; Su, Q.; Burdick, M.J.; Lee, J.; Sundaresan, T.; Pastorino, S.; Park, J.K.; Mikolaenko, I.; Maric, D.; Eberhart, C.G.; Fine, H.A. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res., 2005, 65(6), 2353-2363.
42. Limbourg, F.P.; Takeshita, K.; Radtke, F.; Bronson, R.T.; Chin, M.T.; Liao, J.K. Essential role of endothelial Notch1 in angiogenesis. Circulation, 2005, 111(14), 1826-1832.
43. Seifert, A.; Allan, L.A.; Clarke, P.R. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine. FEBS J., 2008, 275(24), 6268-6280.
44. Seifert, A.; Clarke, P.R. p38alpha-and DYRK1A-dependent phosphorylation of caspase-9 at an inhibitory site in response to hyperosmotic stress. Cell Signal., 2009, 21(11), 1626-1633.
45. Simpson, C.D.; Anyiwe, K.; Schimmer, A.D. Anoikis resistance and tumor metastasis. Cancer Lett., 2008, 272(2), 177-185.
46. Lamoral-Theys, D.; Pottier, L.; Kerff, F.; Dufrasne, F.; Proutière, F.; Wauthoz, N.; Neven, P.; Ingrassia, L.; Van Antwerpen, P.; Lefranc, F.; Gelbcke, M.; Pirotte, B.; Kraus, J.L.; Nève, J.; Kornienko, A.; Kiss, R.; Dubois, J. Simple di-and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli. Bioorg Med. Chem., 2010, 18(11), 3823-3833.
47. Allen, T.D.; Zhu, C.Q.; Jones, K.D.; Yanagawa, N.; Tsao, M.S.; Bishop, J.M. Interaction between MYC and MCL1 in the Genesis and Outcome of Non-Small-Cell Lung Cancer. Cancer Res., 2011, 71(6), 2212-2221.
48. Soengas, M.S.; Lowe, S.W. Apoptosis and melanoma chemoresistance. Oncogene, 2003, 22(20), 3138-3151.
49. Mathieu, V.; Pirker, C.; Martin de Lassalle, E.; Vernier, M.; Mijatovic, T.; De Neve, N.; Gaussin, J.F.; Dehoux, M.; Lefranc, F.; Berger, W.; Kiss, R. The sodium pump alpha1sub-unit: a disease progressionrelated target for metastatic melanoma treatment. J. Cell. Mol. Med., 2009, 13(9B), 3960-3972.
50. Bruyère, C.; Lonez, C.; Duray, A.; Cludts, S.; Ruysschaert, J.M.; Saussez, S.; Yeaton, P.; Kiss, R.; Mijatovic, T. Considering temozolomide as a novel potential treatment for esophageal cancer. Cancer, 2011, 117(9), 2004-2016.
51. Ristorcelli, E.; Lombardo, D. Targeting Notch signaling in pancreatic cancer. Expert Opin. Ther. Targets, 2010, 14(5), 541-552.
52. Lefranc, F.; Brotchi, J.; Kiss, R. Possible future in the treatment of glioblastoma: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol., 2005, 23(10), 2411-2422.
53. Roos, A.K.; Soundararajan, M.; Elkins, J.M.; Fedorov, O.; Eswaran, J.; Phillips, C.; Pike, A.C.W.; Ugochukwu, E.; Muniz, J.R.C.; Burgess-Brown, N.; Von Delft, F.; Arrowsmith, C.H.; Wikstrom, M.; Edwards, A.; Bountra, C.; Knapp, S. Human dual-specificity tyrosine-phosphorylation-regulated kinase 1A in a complex with a consensus substrate peptide. 2009, Protein Data Bank entry 2WO6.
54. Ogawa, Y.; Nonaka, Y.; Goto, T.; Ohnishi, E.; Hiramatsu, T.; Kii, I., Yoshida, M.; Ikura, T.; Onogi, H.; Shibuya, H.; Hosoya, T.; Ito, N.; Hagiwara, M. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat. Commun., 2010, 7, 1-9.
55. Adayev, T.; Wegiel, J.; Hwang, Y.W. Harmine is an ATPcompetitive inhibitor for dual-specificity tyrosine phosphorylationregulated kinase 1A (Dyrk1A). Arch. Biochem. Biophys., 2011, 507(2), 212-218.
56. Himpel, S.; Panzer, P.; Eirmbter, K.; Czajkowska, H.; Sayed, M.; Packman, L.C.; Blundell, T.; Kentrup, H.; Grötzinger, J.; Joost, H.G.; Becker, W. Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem. J., 2001, 359(Pt 3), 497-505.
57. Koo, K.A.; Kim, N.D.; Chon, Y.S.; Jung, M.S.; Lee, B.J.; Kim, J.H.; Song, W.J. QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(8), 2324-2328.
58. Cozza, G.; Mazzorana, M.; Papinutto, E.; Bain, J.; Elliott, M.; di Maira, G.; Gianoncelli, A.; Pagano, M.A.; Sarno, S.; Ruzzene, M.; Battistutta, R.; Meggio, F.; Moro, S.; Zagotto, G.; Pinna, L.A. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem. J., 2009, 421(3), 387-395.
59. Sarno, S.; De Moliner, E.; Ruzzene, M.; Pagano, M. A.; Battistutta, R.; Bain, J.; Fabbro, D.; Schoepfer, J.; Elliott, M.; Furet, P.; Meggio, F.; Zanotti, G.; Pinna, L.A. Biochemical and threedimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a) quinazolin-7-yl] acetic acid (IQA). Biochem. J., 2003, 374(Pt 3), 639-646.
60. Echalier, A.; Bettayeb, K.; Ferandin, Y.; Lozach, O.; Clément, M.; Valette, A.; Liger, F.; Marquet, B.; Morris, J.C.; Endicott, J.A.; Joseph, B.; Meijer, L. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J. Med. Chem., 2008, 51(4), 737-751.
61. Adayev, T.; Chen-Hwang, M.C.; Murakami, N.; Wegiel, J.; Hwang, Y.W. Kinetic properties of a MNB/DYRK1A mutant suitable for the elucidation of biochemical pathways. Biochemistry, 2006, 45(39), 12011-12019.
62. Murray, J.T.; Campbell, D.G.; Morrice, N.; Auld, G.C.; Shpiro, N.; Marquez, R.; Peggie, M.; Bain, J.; Bloomberg, G.B.; Grahammer, F.; Lang, F.; Wulff, P.; Kuhl, D.; Cohen, P. Exploitation of KESTREL to identify NDRG family Members as physiological substrates for SGK1 and GSK3. Biochem. J., 2004, 384(Pt 3), 477-488.
63. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C.J.; McLauchlan, H.; Klevernic, I.; Arthur, J.S.C.; Alessi, D.R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update. Biochem. J., 2007, 408(403), 297-315.
64. Carreaux, F.; Bazureau, J.P.; Renault, S.; Meijer, L.; Lozach, O. Preparation of imidazolone derivatives, derivatives of marine alkaloid Leucettamine B as dual specificity tyrosine-regulated kinase-1A inhibitors. W.O. Patent 2009050352, April 23, 2009.
65. Falà, F.; Blalock, W.L.; Tazzari, P.L.; Cappellini, A.; Chiarini, F.; Martinelli, G.; Tafuri, A.; McCubrey, J.A.; Cocco, L.; Martelli, A.M. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia. Mol Pharmacol., 2008 74(3), 884-95.
66. Liu, X.; Shi, Y.; Woods, K.W.; Hessler, P.; Kroeger, P.; Wilsbacher, J.; Wang, J.; Wang, J.Y.; Li, C.; Li, Q.; Rosenberg, S.H.; Giranda, V.L.; Luo, Y. Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. Neoplasia, 2008, 10(8), 828-837.
67. Bain, J.; McLauchlan, H.; Elliot, M.; Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J., 2003, 371(Pt1), 199-204.
68. Bettayeb, K.; Sallam, H.; Ferandin, Y.; Popowycz, F.; Fournet, G.; Hassan, M.; Echalier, A.; Bernard, P.; Endicott, J.; Joseph, B.; Meijer, L. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Mol. Cancer. Ther., 2008, 7(9), 2713-2724.
69. Mott, B.T.; Tanega, C.; Shen, M.; Maloney, D.J.; Shinn, P.; Leister, W.; Marugan, J.J.; Inglese, J.; Austin, C.P.; Misteli, T.; Auld, D.S.; Thomas, C.J. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Bioorg. Med. Chem. Lett., 2009, 19(23), 6700-6705.
70. Pagano, M.A.; Bain, J.; Kazimierczuk, Z.; Sarno, S.; Ruzzene, M.; Di Maira, G.; Elliott, M.; Orzeszko, A.; Cozza, G.; Meggio, F.; Pinna, L.A. The selectivity of inhibitors of protein kinase CK2: an update. Biochem. J., 2008, 415(3), 353-365.
71. Golub, A. G.; Yakovenko, O.Y.; Bdzhola, V.G.; Sapelkin, V.M.; Zien, P.; Yarmoluk, S.M. Evaluation of 3-Carboxy-4(1H)-quinolones as Inhibitors of human protein kinase CK2. J. Med. Chem., 2006, 49(22), 6443-6450.
72. Wang, Z.; Bhattacharya, N.; Meyer, M.K.; Seimiya, H.; Tsuruo, T.; Tonani, J.A.; Magnuson, N.S. Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Arch. Biochem. Biophys., 2001, 390(1), 9-18.
73. Sliman, F.; Blairvacq, M.; Durieu, E.; Meijer, L.; Rodrigo, J.; Desmaële, D. Identication and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1kinase. Bioorg. Med. Chem. Lett., 2010, 20(9), 2801-2805.
74. Akue-Gedu, R.; Debiton, E.; Ferandin, Y.; Meijer, L.; Prudhomme, M.; Anizon, F.; Moreau, P. Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins. Bioorg. Med. Chem., 2009, 17(13), 4420-4424.
75. Bamford, M.J.; Bailey, N.; Davies, S.; Dean, D.K.; Francis, L.; Panchal, T.A.; Parr, C.A.; Sehmi, S.; Steadman, J.G.; Takle, A.K.; Townsend, J.T.; Wilson, D.M. (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3 ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(14), 3407-3411.
76. Meijer, L.; Galons, H.; Joseph, B.; Popowycz, L.; Oumata, N. Preparation of pyrazolo[1,5-a]-1,3,5-triazine derivatives as inhibitors of cyclin-dependent kinases, casein kinase 1 and DYRK1A kinase for treating diseases including B-cell chronic lymphoid leukemia. W.O. Patent 2010103486, September 16 2010.
77. Coulthard, C.E.; Levene, H.H.; Pyman, F.L. The chemotherapy of derivatives of harmine and harmaline. I. Biochem. J., 1933, 27(3), 727-739.
78. Sanchez-Ramos, J.R. Banisterine and Parkinson's disease. Clin. Neuropharmacol., 1991, 14(5), 391-402.
79. Ishida, J.; Wang, H.K.; Bastow, K.F.; Hu, C.Q.; Lee, K.H. Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs. Bioorg. Med. Chem. Lett., 1999, 9(23), 3319-3324.
80. Hamsa, T.P.; Kuttan, G. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur. J. Pharmacol., 2010, 649(1-3), 64-73.
81. Kim, H.; Sablin, S.O.; Ramsay, R.R. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch. Biochem. Biophys., 1997, 337(1), 137-142.
82. Ma, Y.; Wink, M. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother. Res., 2010, 24(1), 146-149.
83. Baunbaek, D.; Trinkler, N.; Ferandin, Y.; Lozach, O.; Ploypradith, P.; Rucirawat, S.; Ishibashi, F.; Iwao, M.; Meijer, L. Anticancer alkaloid lamellarins inhibit protein kinases. Mar. Drugs, 2008, 4(6), 514-527.
84. Ballot, C., Kluza, J.; Lancel, S.; Martoriati, A.; Hassoun, S.M.; Mortier, L.; Vienne, J.C.; Briand, G.; Formstecher, P.; Bailly, C.; Nevière, R.; Marchetti, P.; Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D. Apoptosis, 2010, 15(7), 769-781.
85. Gallego, M.A.; Ballot, C.; Kluza, J.; Hajji, N.; Martoriati, A.; Castéra, L.; Cuevas, C.; Formstecher, P.; Joseph, B.; Kroemer, G.; Bailly, C.; Marchetti, P. Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway. Oncogene, 2008, 27(14), 1981-1992.
86. Sánchez, C.; Salas, A.P.; Braña, A.F.; Palomino, M.; Pineda-Lucena, A.; Carbajo, R.J.; Méndez, C.; Moris, F.; Salas, J.A. Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles. Chem. Commun. (Camb.), 2009, (27) 4118-4120.
87. Lamoral-Theys, D.; Pottier, L.; Dufrasne, F.; Nève, J.; Dubois, J.; Kornienko, A.; Kiss, R.; Ingrassia, L. Natural polyphenols that display anticancer properties through inhibition of kinase activity. Curr. Med. Chem., 2010, 17(9), 812-825.
88. Folmer, F.; Blasius, R.; Morceau, F.; Tabudravu, J.; Dicato, M.; Jaspars, M.; Diederich, M. Inhibition of TNFalpha-induced activation of nuclear factor kappaB by kava (Piper methysticum) derivatives. Biochem. Pharmacol., 2006, 71(8), 1206-1218.
89. Zi, X.; Simoneau, A.R. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res., 2005, 65(8), 3479-3486.
90. Guedj, F.; Sébrié, C.; Rivals, I.; Ledru, A.; Paly, E.; Bizot, J.C.; Smith, D.; Rubin, E.; Gillet, B.; Arbones, M.; Delabar, J.M. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One, 2009, 4(2), e4606.
91. Göckler, N.; Jofre, G.; Papadopoulos, C.; Soppa, U.; Tejedor, F.J.; Becker, W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J., 2009, 276(21), 6324-6337.
92. Rosenthal A. S.; Tanega C.; Shen M.; Mott B. T.; Bougie J. M.; Nguyen D-T.; Misteli T.; Auld D.S., Maloney D. J.; Thomas C. J. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylationregulated kinases (Dyrk) Bioorg. Med. Chem. Lett., 2011, 21(10), 3152-3158.
93. Pagano, M. A.; Andrzejewska, M.; Ruzzene, M.; Sarno, S.; Cesaro, L.; Bain, J.; Elliott, M.; Meggio, F.; Kazimierczuk, Z.; Pinna, L.A. Optimization of Protein Kinase CK2 Inhibitors Derived from 4,5,6,7-Tetrabromobenzimidazole. J. Med. Chem., 2004, 47, 6239-6247.
94. Vadivelan, S.; Sinha, B. N.; Tajne, S.; Jagarlapudi, S.A. Fragment and knowledge-based design of selective GSK-3_inhibitors using virtual screening models. Eur. J. Med. Chem., 2009, 44(6), 2361-2371.
95. Muraki, M.; Ohkawara, B.; Hosoya, T.; Onogi, H.; Koizumi, J.; Koizumi, T.; Sumi, K.; Yomoda, J-I.; Murray, M.V.; Kimura, H.; Furuichi, K.; Shibuya, H.; Krainer, A. R; Suzuki, M.; Hagiwara, M. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J. Biol. Chem., 2004, 279, 24246-24254.
96. Meijer, L.; Bettayeb, K.; Galons, H. In Monographs on enzyme inhibitors; Yue, E.; Smith, J.P. Ed.; CRC Press, Taylor and Francis: Boca Raton, FL, 2006; Vol. 2, pp. 187-226.
97. Walker, E.H.; Pacold, M.E.; Perisic, O.; Stephens, L.; Hawkins, P.T.; Wymann, M.P.; Williams, R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell., 2000, 6(4), 909-19.